Previous close | 28.18 |
Open | 28.24 |
Bid | 28.01 x 4000 |
Ask | 27.99 x 3000 |
Day's range | 27.92 - 28.28 |
52-week range | 25.20 - 40.37 |
Volume | |
Avg. volume | 42,440,100 |
Market cap | 159.684B |
Beta (5Y monthly) | 0.58 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.68 (6.00%) |
Ex-dividend date | 09 May 2024 |
1y target est | N/A |
Novavax stock popped Friday on news of a licensing deal and minority stake from Big Pharma player Sanofi.
As the big drugmaker tries to turn its fortunes around by focusing on oncology, it has turned to a Citi analyst who hasn’t recommended the stock in over a decade. But Andrew Baum has something Pfizer needs: oncology expertise.
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Visa Inc. (V) and Pfizer Inc. (PFE).